Home/Pipeline/ExoPTEN

ExoPTEN

Acute Spinal Cord Injury

PreclinicalActive

Key Facts

Indication
Acute Spinal Cord Injury
Phase
Preclinical
Status
Active
Company

About NurExone Biologic

Exosome‑powered regenerative therapies for CNS injuries, leveraging a scalable nanodrug platform.

View full company profile

Other Acute Spinal Cord Injury Drugs

DrugCompanyPhase
AMFX-200SAmphix BioPreclinical
ES135Eusol BiotechPhase 3
OPC1Lineage Cell TherapeuticsPhase 1/2a